Abstract

A robust manufacturing process and the relationship between intermediate quality attributes (IQAs), critical quality attributes (CQAs), and critical process parameters (CPPs) for high-shear wet granulation was determined in this study. Based on quality by the design (QbD) approach, IQAs, CQAs, and CPPs of a telmisartan tablet prepared by high-shear wet granulation were determined and then analyzed with multivariate analysis (MVA) to evaluate mutual interactions between IQAs, CQAs, and CPPs. The effects of the CPPs on the IQAs and CQAs were quantitatively predicted with empirical models of best fit. The models were used to define operating space, and an evaluation of the risk of uncertainty in model prediction was performed using Monte Carlo simulation. MVA showed that granule size and granule hardness were significantly related to % dissolution. In addition, granule FE (Flow Energy) and Carr’s index had effects on tablet tensile strength. Using the manufacture of a clinical batch and robustness testing, a scale-up from lab to pilot scale was performed using geometric similarity, agitator torque profile, and agitator tip speed. The absolute biases and relative bias percentages of the IQAs and CQAs generated by the lab and pilot scale process exhibited small differences. Therefore, the results suggest that a risk reduction in the manufacturing process can be obtained with integrated process parameters as a result of the QbD approach, and the relationship between IQAs, CQAs, and CPPs can be used to predict CQAs for a control strategy and SUPAC (Scale-Up and Post-Approval Guidance).

Highlights

  • Pharmaceutical manufacturing processes are complex and controlled by multi-factorial relationships between materials and process parameters

  • This suggests that the integrated process parameters obtained from experimental design at the lab scale could be applied at the pilot scale with the scale-up strategy

  • Based on the control strategy, the development of process parameters for high-shear wet granulation was studied at the lab scale with the quality by the design (QbD) approach

Read more

Summary

Introduction

Pharmaceutical manufacturing processes are complex and controlled by multi-factorial relationships between materials and process parameters. It is difficult to investigate the pharmaceutical manufacturing process with the OFAT (one-factor-at-a-time) method. Combination approaches, such as experimental design and MVA, could present a comprehensive and intensive understanding of the relevant multi-factorial relationships between process parameters and product quality attributes [1,2]. The relationship between control factors and response factors is statistically analyzed with analysis of variance. MVA can be regarded as a complementary method to experimental design, which presents additional information about the product and processes, such as the effect of intermediate quality attributes on product quality attributes. When MVA and experimental design are combined, the integrated MVA is a more powerful tool to elucidate the complex relationships in the pharmaceutical manufacturing process

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call